Skip to content
naulon
Not checkedNot checked for notices yet.

Pediatric genitourinary tumors: Distribution, demographics, and outcomes

Azadeh Nazemi, Siamak Daneshmand, Andy Chang

Pediatric Investigation · 2022

doi:10.1002/ped4.12318 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

ABSTRACT Importance The diversity of pediatric genitourinary malignancies requires a timely resource detailing tumor characteristics and survival. Objective To determine the incidence, demographics, and outcomes of all pediatric genitourinary tumors within the United States. Methods A population‐based search for patients diagnosed with genitourinary cancers under age 15 was performed using the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 registry. Information on primary tumor location, histologic type, patient age, sex, year of diagnosis, race, treatment, cause of death, and survival months was extracted. Descriptive epidemiological and survival statistics were calculated for all variables. Results A total of 4576 cases from 1973 through 2015 were identified. The most common primary tumor sites were the kidney (80.3%), testis (12.3%), bladder (2.8%), and vagina (1.5%). Nephroblastoma (87.9%) and sarcoma (3.4%) were the most common renal malignancies. Rhabdomyosarcoma was common in the vagina, bladder, and testis at rates of 66.2%, 61.2%, and 24.6%, respectively. Germ cell tumors (71.0%) were the most common primary tumor of the testis. Ten‐year overall survival (OS) for renal nephroblastoma and sarcoma was 88% and 82%, respectively. Ten‐year OS for RMS of the testis was 91%, the bladder was 79%, the vagina was 79%, and the prostate was 56%. Germ cell tumor 10‐year OS were 96% in the testis and 100% in the vagina. Interpretation A better understanding of the overall distribution and outcomes associated with pediatric genitourinary cancers allows physicians to best understand the patient's disease in the context of current frequency in a genitourinary setting and reported outcomes.

Abstract licence: CC BY-NC-ND

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.